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Abstract: This analysis examined patient-reported attitudes toward antipsychotic medication 
and the relationship of these attitudes with clinical outcomes and pharmacotherapy adherence. 
The analysis included three randomized, double-blind studies in patients with schizophrenia, 
schizoaffective disorder, or schizophreniform disorder diagnosed according to the Diagnostic 
and Statistical Manual of Mental Disorders 4th Edition and randomly assigned to treatment 
with olanzapine 5–20 mg/day or another antipsychotic (haloperidol 2–20 mg/day, risperidone 
2–10 mg/day, or ziprasidone 80–160 mg/day). Patient-reported improvements were significantly 
greater for olanzapine (n = 488) versus other treatments (haloperidol n = 145, risperidone n = 158, 
or ziprasidone n = 271) on multiple Drug Attitude Inventory items. A positive attitude toward 
medication reported by patients was significantly associated with greater clinical improvement on 
the Positive and Negative Syndrome Scale and lower discontinuation rates. These results suggest 
that patients’ perceptions of treatment benefits are associated with objective clinical measures, 
including reduction of symptom severity and lower discontinuation rates. Furthermore, olan-
zapine may be associated with more positive treatment attitudes. These findings may contribute 
to a better understanding of reasons for treatment adherence from patients’ own perspectives.
Keywords: antipsychotic agents, medication adherence, patient satisfaction, schizophrenia, 
treatment efficacy
Introduction
Nonadherence to pharmacotherapy has long been recognized as a problem in the 
treatment of schizophrenia. Even the most conservative estimates indicate a discontinu-
ation rate in naturalistic studies of approximately half of all patients within one year 
of their most recent episode.1,2 A 2008 analysis of Medicaid prescription records for 
5898 patients with schizophrenia revealed that more than 90% of patients discontinued 
treatment within a year of filling their first (index) prescriptions.3 Nonadherence to 
treatment is associated with poorer clinical and functional outcomes, increased use of 
emergency psychiatric services, and an increased number of hospitalizations.4,5 In fact, 
noncompliance is the leading contributor to relapse,6,7 and the overwhelming majority of 
patients with schizophrenia who require hospitalization have generally been noncompli-
ant in the period leading up to their most recent episode.6 Conversely, longer duration 
of treatment is associated with reduced rates of relapse and hospitalization.8
Numerous studies have found that type of medication may influence treatment 
nonadherence. In some studies, the use of atypical antipsychotics was seen to be 
associated with greater treatment adherence relative to conventional neuroleptics,9–11 
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risk of extrapyramidal symptoms during treatment with 
the atypical medications should confer greater adherence 
to treatment.12,13 Moreover, some research suggests that 
patients receiving atypical antipsychotics have more favor-
able subjective responses to their current medication than 
those receiving conventional medications.14–16 However, other 
studies report no difference or suggest patient characteristics 
may be responsible for differences in adherence rather than 
type of medication.17
The health belief model suggests that patient likelihood 
to continue with medication intake is a product of an implicit 
and subjective assessment of the relative risks and benefits of 
the medicine in relation to personal goals and constraints.)18–20 
In this model, patients are more likely to stay on treatment 
when they believe that their need for treatment and the ben-
efits of treatment outweigh the negative aspects.
The potential association between patients’ subjective 
attitudes toward medication and treatment adherence, as 
well as objective symptom responsiveness, has not been 
fully characterized and deserves greater research atten-
tion. To explore this relationship, this analysis examined 
differences in patients’ attitudes toward treatment with 
olanzapine, haloperidol, risperidone, and ziprasidone, 
and how these attitudes might be related to differences 
in discontinuation rates and improvements in symptom 
severity.
Methods
Studies
This was a post hoc analysis of clinical trials within the Eli 
Lilly and Company olanzapine database. The selection cri-
teria for the clinical trials included in this research were (1) 
randomized, double-blind, active comparator, (2) involving 
a minimum of 50 patients, and (3) having collected both the 
Positive and Negative Syndrome Scale (PANSS)21 and the 
Drug Attitude Inventory 10-item version (DAI-10).22 Three 
studies met these criteria and formed the basis of this analysis. 
All were large multicenter trials performing head-to-head 
comparisons of the safety and efficacy of olanzapine with 
another antipsychotic. Study 1 (F1D-MC-HGGN, completed 
before initiation of the Clinical Trial Registry) was conducted 
at 39 sites in the US and Canada, and compared the safety and 
efficacy of olanzapine, haloperidol, and risperidone.23 Study 
2 (F1D-MC-HGHJ, Clinical Trial Registry #NCT00036088) 
was conducted at 79 sites in North and South America and 
Europe, and compared olanzapine and ziprasidone.24 Study 3 
(F1D-US-HGHO, completed before initiation of the   Clinical 
Trial Registry) was conducted at 18 sites in the US, and 
compared olanzapine plus lorazepam with haloperidol plus 
lorazepam.25 Studies 1 and 2 were both long-term trials, with 
Study 1 conducted over 12 months and Study 2 conducted 
over 28 weeks. Study 3 was a short-term study conducted 
over three weeks.
Patient sample
Participating subjects were adult (18–65 years) male or female 
patients. In Study 1, participants were inpatients or outpatients 
who had met the diagnostic criteria for schizophrenia or schizo-
affective disorder, as defined by the Diagnostic and Statistical 
Manual of Mental Disorders, 4th Edition (DSM-IV),26 and had a 
minimum baseline score of 4 on at least two items of the PANSS 
positive subscale and a minimum score of 18 (ie, individual 
item score range 0–6, total range 0–108) on the 18-item Brief 
Psychiatric Rating Scale (BPRS).27 In Study 2, participants 
were inpatients or outpatients who met the DSM-IV diagnostic 
criteria for schizophrenia and had a minimum score of 4 on 
the Clinical Global Impressions–Severity scale (CGI-S)28 and 
a baseline score of at least 42 (ie, individual item score range 
1–7; total range 18–126) on the BPRS, with a score of 4 or more 
on at least one of the PANSS positive subscale items. In Study 
3, the sample consisted of acutely psychotic patients who were 
initially inpatients and who met the DSM-IV diagnostic crite-
ria for schizophrenia, or schizophreniform or schizoaffective 
disorder. Patients had a minimum score of 20 on the PANSS 
agitation subscale (range 0–60) and a CGI-S score of at least 
4 at baseline. Female patients of childbearing potential were 
required to be using a medically accepted means of contracep-
tion (for Study 3 only).
Patients with any acute, serious, or unstable medical 
conditions, including inadequately controlled diabetes, 
hepatic insufficiency, recent cerebrovascular accidents, 
uncontrolled seizure disorders, serious acute systemic infec-
tion, or immunologic disease, or unstable cardiovascular 
disorder were excluded. Also excluded were any patients 
who had undergone treatment with an injectable depot antip-
sychotic within one dosing interval before randomization. 
Before participation, patients or their legal representatives 
each received a complete description of their study and 
signed an informed consent document approved by the 
investigative site’s institutional review board. All studies 
were conducted under the principles of the Declaration of 
Helsinki.29
Treatments
Each of the three studies included in this analysis was a 
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with oral olanzapine with another orally administered atypical 
antipsychotic or haloperidol. Studies 1 and 2 began with a wash-
out and placebo lead-in period lasting from two to nine days 
before treatment randomization. In Study 1, patients were ran-
domly assigned to treatment with either olanzapine 5–20 mg/
day, haloperidol 2–19 mg/day, or risperidone 2–10 mg/day for 
up to 12 months, whereas in Study 2, patients were assigned 
to either olanzapine 10–20 mg/day or ziprasidone 80–160 mg/
day (the latter administered in split, twice-daily doses) for up to 
28 weeks. In Study 3, the washout period was applied for up to 
24 hours, after which patients were assigned to either olanzapine 
10–20 mg/day plus lorazepam as needed for behavioral agita-
tion, or haloperidol 10–20 mg/day plus lorazepam as needed, for 
up to three weeks. As the trial progressed, the use of adjunctive 
lorazepam was gradually restricted so that by the middle of the 
third week, patients were no longer receiving lorazepam.
Assessments
The PANSS is an assessment tool that measures the severity 
of psychiatric symptoms of psychosis. It consists of 30 items, 
each rated on a scale from 1 = absent to 7 = extreme, with 
totals ranging from 30 to 210. In addition to the PANSS total 
score, this analysis examines changes in the five dimensions 
proposed by Davis and Chen,30 ie: depressive, which includes 
symptoms of anxiety (Items 15–17 and 20); disorganized 
thought (Items 12, 18, 19, 24, 25, and 27); hostility, which 
includes symptoms of excitement and impulsivity (Items 4, 
7, 22, and 28); negative, which includes negative symptoms 
(Items 8–11, 13, 21, and 30); and positive, which includes 
positive symptoms (Items 1–3, 5, 6, 14, 23, 26, and 29).
The DAI-10 is a 10-item, self-reported scale, extracted from 
the full 30-item version of the DAI,22 that measures subjective 
feelings of patients with schizophrenia toward their current 
medications. The DAI-10 total score is the sum of Items 1 
through 10, and individual items are scored as either “0”, which 
means “no” or “1”, which means “yes” based on whether the 
patient agrees with the statement. Items 1, 3, 4, 7, 9, and 10 
reflect positive attitudes toward the current medication, while 
items 2, 5, 6, and 8 reflect negative attitudes.
Analyses
Separate comparisons between treatments were made in a 
head-to-head fashion between olanzapine and each of the 
three active comparators in turn, in order to allow for fair 
comparisons of each pair of drugs based on the same studies. 
Data for head-to-head comparison of olanzapine and risperi-
done were obtained from Study 1, while data for comparison 
of olanzapine and ziprasidone were obtained from Study 2. 
Data for comparison of olanzapine and haloperidol were 
pooled from Studies 1 and 3.
Baseline treatment differences for categoric variables (eg, 
demographics and diagnostic categories) were analyzed via 
Fisher’s exact test, while continuous variables (eg, age and 
PANSS) were analyzed by analysis of variance with term 
for treatment. Treatment differences in rates of endpoint 
responses (ie, agreement or disagreement) with DAI-10 items 
were analyzed using Fisher’s exact test. To explore potential 
associations between differences in attitude to treatment on 
the one hand and differences in completion rates or PANSS 
scores on the other, completion rates and PANSS subscale 
scores were compared between patients responding with 
agreement to each DAI-10 item and those responding with 
disagreement, using Fisher’s exact test to compare comple-
tion rates and analysis of variance (last observation carried 
forward) to compare PANSS scores. All tests in this report 
are based on a two-tailed α significance of 0.05.
Results
Patient demographics and baseline 
characteristics
A total of 1221 patients were represented in these analyses 
(Table 1), roughly evenly randomized to treatment with either 
olanzapine (n = 647) or one of the other antipsychotics (all 
other antipsychotics n = 574 [haloperidol n = 145, risperidone 
n = 158, ziprasidone n = 271]). The majority of patients were 
male (68.2%), and most had received a diagnosis of schizo-
phrenia (81.8%), with smaller numbers receiving diagnoses 
of schizoaffective disorder (18.0%) or schizophreniform 
disorder (0.2%). Racially or ethnically, the sample was com-
posed primarily of patients of Caucasian (51.4%) origin, with 
lower proportions identifying themselves as of African origin 
(28.2%), Hispanic ethnicity (13.8%), East Asian (1.4%), West 
Asian (0.4%), or “other” (4.8%). The mean age in all three 
studies was in the late 30s, with a mean age at onset of illness 
in the early 20s. Baseline PANSS total scores indicated a mean 
illness severity in the moderate range. No significant differ-
ence was seen in any demographic characteristic between 
patients assigned to olanzapine treatment and those assigned 
to any other antipsychotic agent (Table 1).
Mean change in PAnSS total and subscale 
scores from baseline to endpoint
When compared with patients treated with haloperidol, 
patients treated with olanzapine had significantly greater 
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Table 1 Patient demographics and baseline characteristics
Measure Olanzapine versus haloperidol Olanzapine versus risperidone Olanzapine versus ziprasidone
Olanzapine 
(n = 211)
Haloperidol 
(n = 145)
P value Olanzapine 
(n = 159)
Risperidone 
(n = 158)
P value Olanzapine 
(n = 277)
Ziprasidone 
(n = 271)
P value
Age, years,  
mean (SD)
38.6 (8.4) 39.7 (8.6) 0.20 38.4 (7.9) 39.5 (8.3) 0.23 40.1 (11.6) 38.2 (12.1) 0.07
Age at onset, 
mean (SD)
22.6 (6.9) 22.0 (7.2) 0.41 23.0 (7.0) 23.3 (7.2) 0.72 23.9 (8.3) 22.8 (8.2) 0.11
Males, % 72.0 71.0 0.90 72.3 70.2 0.71 65.0 63.5 0.72
racial/ethnic  
origin, n (%)
0.27 0.31 0.77
  African 62 (29.4) 52 (35.9) 43 (27.0) 43 (27.2) 78 (28.2) 66 (24.4)
  caucasian 121 (57.3) 71 (49.0) 95 (59.7) 101 (63.9) 115 (41.5) 124 (45.8)
  east Asian 5 (2.4) 2 (1.4) 3 (1.9) 2 (1.3) 2 (0.7) 3 (1.1)
  hispanic 15 (7.1) 11 (7.6) 13 (8.2) 6 (3.8) 63 (22.7) 61 (22.5)
  South Asian 2 (1.0) 0 (0.0) 2 (1.3) 0 (0.0) 1 (0.4) 0 (0.0)
  Other 6 (2.8) 9 (6.2) 3 (1.9) 6 (3.8) 18 (6.5) 17 (6.3)
Diagnosis, n (%) 0.96 0.14 –
  Schizophrenia 135 (64.0) 94 (64.8) 105 (66.0) 117 (74.0) 277 (100.0) 271 (100.0)
  Schizoaffective 75 (35.6) 50 (34.5) 54 (34.0) 41 (26.0) 0 (0.0) 0 (0.0)
  Schizophreniform 1 (0.5) 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Baseline PAnSS  
total, mean (SD)
87.2 (16.5) 88.5 (17.6) 0.47 82.6 (13.1) 84.2 (14.7) 0.32 99.8 (19.1) 102.0 (21.2) 0.19
Mean modal dose  
(mg/day), mean
14.0 16.4 – 12.3 5.2 – 15.3 116.0 –
Abbreviations: PAnSS, Positive and negative Syndrome Scale; SD, standard deviation.
as the depressive (P = 0.012) and disorganized thought 
(P = 0.025) subscale scores at endpoint. In comparison 
with patients treated with risperidone, patients treated with 
olanzapine has significantly greater improvements on the 
disorganized thought subscale at endpoint (P = 0.011). 
Lastly, olanzapine treatment was associated with significantly 
greater improvements on the PANSS total score, as well as 
the depressive, disorganized thoughts, hostility, negative, and 
positive subscale scores at endpoint when compared with 
patients treated with ziprasidone (all P , 0.001, Table 2).
comparison of patient attitudes  
to treatment: DAi-10 scores
Olanzapine treatment was associated with higher percent-
ages of patients reporting a positive attitude on the majority 
of DAI-10 items relative to the other three medications 
(Table 3). These differences reached statistical significance 
for six items in the comparisons with haloperidol (Items 1, 
2, 4, 5, 7, and 9), two items in the comparisons with risperi-
done (Items 1 and 4), and one item in the comparisons with 
ziprasidone (Item 2).
Patient attitudes and adherence
When pooled across antipsychotic medications, patients with 
a positive attitude toward their medication had a significantly 
greater likelihood of completing their treatment (see Figure 1). 
On every item of the DAI-10, patients reporting a positive 
attitude toward treatment had significantly higher completion 
rates than did those reporting a negative attitude. Differences 
were the greatest for items 1 (positive response = agreement 
Table 2 changes in Positive and negative Syndrome Scale total and subscale scores at endpoint, by treatment
PANSS scale Olanzapine versus haloperidol Olanzapine versus risperidone Olanzapine versus ziprasidone
Olz Hal P value Olz Ris P value Olz Zip P value
Total −16.7 −12.6 0.011 −12.4 −9.5 0.054 −35.7 −26.0 ,0.001
Depressive −2.3 −1.7 0.012 −2.0 –1.6 0.18 −3.9 −3.0 ,0.001
Disorganized  
thought
−2.8 −2.1 0.025 −1.9 −1.3 0.011 −6.0 −4.1 ,0.001
hostility −2.0 −1.8 0.26 −0.9 −0.6 0.54 −4.2 −2.6 ,0.001
negative −3.1 −2.1 0.07 −2.6 −1.8 0.10 −8.4 −6.7 ,0.001
Positive −6.4 −5.1 0.08 −5.1 −4.2 0.19 −13.2 −9.6 ,0.001
Abbreviations: hal, haloperidol; Olz, olanzapine; PAnSS, Positive and negative Syndrome Scale; ris, risperidone; Zip, ziprasidone.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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with “For me, the good things about my current medication 
outweigh the bad”) and 10 (positive response = agreement 
with “By staying on my medication, I can prevent getting 
sick”), and lowest – yet still significantly higher for positive 
attitudes – on items 8 (positive response = disagreement 
with “It is unnatural for my mind and body to be controlled 
by medications”) and 3 (positive response = agreement with 
“I take my medications of my own free choice”).
Patient attitudes and symptom control
Across the antipsychotic medications, favorable atti-
tudes toward current treatment were also associated with 
improvements in symptom severity, as shown by greater 
reductions in PANSS subscale scores associated with positive 
attitudes on the individual items of the DAI-10 (Table 4). 
However, no specific symptom clusters reflected patients’ 
attitudes to a greater or lesser degree, and all five subscales 
showed significantly greater score reductions among patients 
reporting positive attitudes than those reporting negative atti-
tudes for most of the items of the DAI-10. Most items of the 
DAI-10 showed a significant correlation with all five PANSS 
dimensions. However, there was essentially no correlation 
between attitude toward treatment and symptom reduction 
for DAI-10 item 8, “It is unnatural for my mind and body to 
Table 3 Drug Attitude inventory items, percent agreeing at endpoint, by treatment
DAI item Olanzapine versus  
haloperidol
Olanzapine versus  
risperidone
Olanzapine versus  
ziprasidone
Olz Hal P value Olz Ris P value Olz Zip P value
01: good outweighs bad 86.3 75.8 0.022 84.4 73.7 0.036 86.5 82.4 0.26
02: Feel weird, like a “zombie” 17.9 35.0 0.001 17.0 20.3 0.53 18.0 25.8 0.037
03: Take meds of own free choice 88.6 86.9 0.72 87.4 84.2 0.49 84.1 80.4 0.34
04: Feel more relaxed 84.8 68.0 0.001 85.2 75.2 0.046 79.2 76.3 0.45
05: Feel tired/sluggish 37.5 50.8 0.025 37.0 39.8 0.71 30.7 35.8 0.25
06: Take meds only when sick 59.2 53.7 0.35 64.4 66.9 0.70 35.5 31.4 0.39
07: Feel more normal 83.5 64.8 ,0.001 83.7 75.9 0.13 74.3 72.5 0.68
08:   Unnatural to be controlled  
by meds
39.1 39.2 .0.99 34.1 37.6 0.61 38.4 37.9 0.93
09: clearer thoughts 81.0 66.9 0.007 81.5 78.9 0.65 74.3 77.1 0.53
10: Med prevents sickness 85.9 77.0 0.07 85.9 78.2 0.11 81.6 82.1 0.91
Abbreviations: DAi, Drug Attitude inventory; hal, haloperidol; Olz, olanzapine; ris, risperidone; Zip, ziprasidone.
10: Med prevents sickness
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08: Unnatural to be controlled...
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be controlled by medications”, which showed no significant 
differences in PANSS score reductions between patients with 
positive versus negative attitudes for any PANSS subscale. 
The correlation was likewise weak for item 3, “I take my 
medications of my own free choice”, which showed a signifi-
cant difference for just the PANSS negative subscale.
Discussion
The principal findings from these analyses demonstrate that 
treatment with olanzapine may be associated with better 
medication perceptions than those for haloperidol, risperi-
done, or ziprasidone. Furthermore, patient subjective attitude 
toward medication is associated with treatment adherence 
and objective measures of symptom responsiveness among 
patients with schizophrenia. Positive attitude toward medica-
tion, as measured by DAI-10, was shown to be associated 
with significantly higher study completion rates and greater 
symptom reduction in all five dimensions of the PANSS.
No particular symptom dimension appeared to have a 
higher or lower association than any other with medication 
attitude. This was unexpected, because numerous studies 
have identified positive symptom severity as the leading 
predictor of higher risk of discontinuation.31–35 Moreover, 
patient compliance36,37 and attitude toward medication15 have 
been linked to PANSS positive subscale scores. However, the 
depressive symptom cluster has also been implicated as an 
important factor in both adherence5,32,35 and attitude toward 
medication,38 as have symptoms of hostility/excitement.5,39 In 
fact, recently published data16 show that, while the positive 
symptom cluster may indeed be the strongest predictor of 
patient attitudes and adherence, a correlation can nevertheless 
be found between adherence and general PANSS symptom 
reduction. Although this study did not explicitly examine the 
association between discontinuation and symptom severity 
within specific symptomatic dimensions, the two do appear 
to have a strong relationship.30,40–42 This, however, has the 
potential to be complicated by other factors, such as dosing 
frequency17,43 and patients’ levels of insight.38,43–45
In this research, symptom severity, adherence to treat-
ment, and attitudes toward medication were examined 
simultaneously. Clearly there is a complex interaction 
between these and other aspects of schizophrenia and its 
treatment, such as a medication’s tolerability and adverse 
event profile, patients’ insight into their own condition, 
and perceived social pressures from the stigma associated 
with having the disease, or indeed of taking medication for 
its alleviation. Studies involving the conventional antipsy-
chotics had earlier implicated the incidence of akathisia 
as a major determinant of treatment discontinuation.17,46 
However, with the increased use of the second-generation, 
atypical antipsychotics, akathisia has become less of an 
issue,9,47 and indeed current thinking is that lack of efficacy, 
rather than tolerability profile, is a stronger predictor of 
early discontinuation.7,35,48–50 Medication noncompliance 
and undercompliance continue to be a problem in the 
treatment of schizophrenia; the vast majority of hospital 
admissions for exacerbation of psychosis have been linked 
to noncompliance,6,51 which may still be the most important 
militating factor in relapse.6
The correlations between patient attitude toward medi-
cation, treatment persistence, and symptom improvement 
in the present research do not suggest a causal relation-
ship. Possibly the positive attitude toward medication has 
contributed to patients staying on treatment longer. It is 
also possible that longer treatment duration helped patients 
to gain better insight, and thus a better perception of the 
medication. Similarly, positive patient attitude and behavior 
may have contributed to improved psychopathology. Con-
versely, improvement in symptoms and the recognition of 
this improvement by patients may have led to improvement 
in their attitude to medication.
A potential limitation of the present analysis is that 
all-cause discontinuation was used to measure treatment 
persistence. In keeping with the objectives of the Clinical 
Antipsychotic Trials of Intervention Effectiveness (CATIE) 
studies,42,52 all-cause discontinuation of treatment had been 
selected for the current set of analyses because it integrates 
patients’ and clinicians’ assessments of efficacy and toler-
ability into a single global measure that reflects a medication’s 
balance of relative benefits and risks. Other limitations that 
warrant mention include the differences in baseline PANSS 
scores and study designs among the source studies, which 
may have been mitigated to some extent by the use of within-
study comparisons and the limited sample sizes. Finally, it 
should be pointed out that the data were all derived from 
clinical trials under controlled conditions and with attendant 
exclusion and inclusion criteria, and therefore the results may 
not be easily extrapolated to the entire population of patients 
with schizophrenia.
In summary, the results of this post hoc analysis indicate 
that patients’ subjective perceptions of treatment benefits 
may be associated with objective clinical measures, includ-
ing reduction of symptom severity and lower discontinuation 
rates. These findings may contribute to a better understanding 
of the patient’s own perspective of antipsychotic treatment 
and its implications for treatment adherence.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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